Literature DB >> 26137123

Diagnosis, complications and management of chronic neutrophilic leukaemia: A case report.

Patrícia Rocha Silva1, Cristina Ferreira1, Susana Bizarro2, Nuno Cerveira2, Lurdes Torres2, Ilídia Moreira1, José Mário Mariz1.   

Abstract

Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm characterized by sustained neutrophilia and the absence of the Philadelphia chromosome or the BCR-ABL1 fusion gene. The present study reports the case of a 59-year-old Caucasian female that was referred to The Francisco Gentil Portuguese Institute of Oncology (Porto, Portugal) with constitutional symptoms (mainly asthenia), marked leukocytosis (51.33×109/l with 90% neutrophils), macrocytic anemia and splenomegaly. Bone marrow aspiration and biopsy revealed hypercellular marrow with clear predominance of segmented neutrophils. The karyotype was normal and the BCR-ABL1 fusion gene was not detected. After excluding a leukemoid reaction, a diagnosis of CNL was established. The clinical follow-up was complicated by hemorrhagic brain lesions and relapsing episodes of erythematous, well-demarcated and painful subcutaneous nodular lesions, consistent with Sweet's syndrome (SS). Multiple treatment strategies were administered, including use of hydroxyurea, imatinib and intensive chemotherapy. Nevertheless, progression was documented and the patient succumbed at 28 months post-diagnosis. The clinical course of CNL varies, and can be complicated by cerebral hemorrhage, blastic transformation or infection. Dermatological manifestations such as SS have seldom been reported in association. No evidence-based treatment currently exists and the majority of our knowledge is based on results from case reports and small series.

Entities:  

Keywords:  Sweet's syndrome; atypical chronic myeloid leukaemia; chronic neutrophilic leukaemia; myeloproliferative disorders

Year:  2015        PMID: 26137123      PMCID: PMC4473643          DOI: 10.3892/ol.2015.3148

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  A case of chronic neutrophilic leukemia with deletion (11)(q23).

Authors:  C Terré; I Garcia; J N Bastie; D Mayeur; L Decombe; P Gruyer; R Berger; S Castaigne
Journal:  Cancer Genet Cytogenet       Date:  1999-04

2.  Bleeding tendency in chronic neutrophilic leukemia.

Authors:  Toshio Shigekiyo; Junko Miyagi; Masahito Chohraku; Kazunori Kawauchi; Etsuko Sekimoto; Atsuhisa Shirakami; Hironobu Shibata
Journal:  Int J Hematol       Date:  2008-06-27       Impact factor: 2.490

3.  Myeloblastic transformation of chronic neutrophilic leukaemia.

Authors:  D Amato; S Memon; C Wang
Journal:  Br J Haematol       Date:  2008-05-28       Impact factor: 6.998

4.  Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)

Authors:  F Pane; F Frigeri; M Sindona; L Luciano; F Ferrara; R Cimino; G Meloni; G Saglio; F Salvatore; B Rotoli
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

5.  Neutrophilic dermatosis associated with chronic neutrophilic leukemia.

Authors:  J Castanet; J P Lacour; G Garnier; C Perrin; B Taillan; J G Fuzibet; J P Ortonne
Journal:  J Am Acad Dermatol       Date:  1993-08       Impact factor: 11.527

6.  Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.

Authors:  In Keun Choi; Byung-Soo Kim; Kyung-A Lee; Sookwon Ryu; Hee Yun Seo; Hyeryoung Sul; Jong Gwon Choi; Hwa Jung Sung; Kyong Hwa Park; So Young Yoon; Sang Cheul Oh; Jae Hong Seo; Chul Won Choi; Sang Won Shin; Soo-Young Yoon; Yunjung Cho; Young-Kee Kim; Yeul Hong Kim; Jun Suk Kim
Journal:  Am J Hematol       Date:  2004-12       Impact factor: 10.047

7.  Chimeric del20q in a case of chronic neutrophilic leukemia.

Authors:  M B Frank; T H Norwood; D M Willerford
Journal:  Am J Hematol       Date:  2000-07       Impact factor: 10.047

8.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

9.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Authors:  Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-X Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Chronic neutrophilic leukemia with congenital Robertsonian translocation successfully treated with allogeneic bone marrow transplantation in a young man.

Authors:  Hideko Goto; Takeshi Hara; Hisashi Tsurumi; Shinobu Tanabashi; Hisataka Moriwaki
Journal:  Intern Med       Date:  2009-04-01       Impact factor: 1.271

View more
  2 in total

Review 1.  Chronic neutrophilic leukemia: new science and new diagnostic criteria.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-13       Impact factor: 11.037

Review 2.  Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management.

Authors:  Thomas P Thomopoulos; Argiris Symeonidis; Alexandra Kourakli; Sotirios G Papageorgiou; Vasiliki Pappa
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.